Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
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
ykg7sCJJPbPHp9mT
Listen
